Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Decanoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 7/20 | 0.72 |
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | CES2 | O00748 | 4/20 | 0.67 |
| ▸ | CES1 | P23141 | 4/20 | 0.67 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8743307 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Stearic Acid SCHEMBL13836877 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Palmitic Acid SCHEMBL141829 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Myristic Acid SCHEMBL360184 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Undecanoate SCHEMBL11343015 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Heptanoate SCHEMBL588180 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Stearic Acid SCHEMBL2371 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Arachidic Acid SCHEMBL7629156 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Stearic Acid SCHEMBL9243538 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Lignoceric Acid SCHEMBL262204 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118496679-B | Preparation method of special calcium-zinc stabilizer for PVC transparent film | 山东振曦新材料科技有限公司 | 2024-10-08 | — | — | CN | claimed |
| CN-118496679-A | Preparation method of special calcium-zinc stabilizer for PVC transparent film | 山东振曦新材料科技有限公司 | 2024-08-16 | — | — | CN | claimed |
| EP-3514148-B1 | LACYLATE SYNTHESIS METHODS USING DILACTIDES | CARAVAN INGREDIENTS INC (US) | 2023-07-26 | — | — | EP | claimed |
| CN-114133852-A | Preparation method of polyurethane-based environment-friendly coating | 成都绮萝科技有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-112467110-A | Organic battery electrode and preparation method thereof | 黄涛 | 2021-03-09 | — | — | CN | claimed |
| EP-2616455-B1 | LACTYLATE SYNTHESIS METHODS USING DILACTIDES | CARAVAN INGREDIENTS INC (US) | 2020-12-02 | — | — | EP | claimed |
| EP-3514148-A1 | LACYLATE SYNTHESIS METHODS USING DILACTIDES | Caravan Ingredients Inc. (US) | 2019-07-24 | — | — | EP | claimed |
| EP-2299998-B1 | MEDIUM-CHAIN LENGTH FATTY ACIDS AND GLYCERIDES AS NEPHROPROTECTION AGENTS | PROMETIC PHARMA SMT LTD (GB) | 2018-01-03 | — | — | EP | claimed |
| US-9682054-B2 | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis | PROMETIC PHARMA SMT LIMITED (GB) | 2017-06-20 | — | — | US | claimed |
| US-9532962-B2 | Medium-chain length fatty acids and glycerides as nephroprotection agents | PROMETIC PHARMA SMT LIMITED (GB) | 2017-01-03 | — | — | US | claimed |
| EP-1474466-B1 | SURFACE TREATMENT OF ETHYLENE-BASED POLYMER PELLETS TO IMPROVE BLOCKING RESISTANCE | DU PONT (US) | 2007-03-28 | — | — | EP | claimed |
| JP-2006516987-A | — | — | 2006-07-13 | — | — | JP | claimed |
| US-20060128800-A1 | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis | PROMETIC PHARMA SMT LIMITED (GB) | 2006-06-15 | — | — | US | claimed |
| EP-1592416-A1 | MEDIUM-CHAIN LENGTH FATTY ACIDS, GLYCERIDES AND ANALOGUES AS STIMULATORS OF ERYTHROPOIESIS | Prometic Biosciences Inc. (CA) | 2005-11-09 | — | — | EP | claimed |
| JP-2004525957-A | — | — | 2004-08-26 | — | — | JP | claimed |
| WO-2004069237-A1 | MEDIUM-CHAIN LENGTH FATTY ACIDS, GLYCERIDES AND ANALOGUES AS STIMULATORS OF ERYTHROPOIESIS | PROMETIC BIOSCIENCES INC. (CA) | 2004-08-19 | — | — | WO | claimed |
| US-20040147599-A1 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | PROMETIC PHARMA SMT LIMITED (GB) | 2004-07-29 | — | — | US | claimed |
| EP-1385498-A2 | MEDIUM-CHAIN LENGTH FATTY ACIDS, GLYCERIDES AND ANALOGUES AS NEUTROPHIL SURVIVAL AND ACTIVATION FACTORS | Prometic Biosciences Inc. (CA) | 2004-02-04 | — | — | EP | claimed |
| WO-2002083120-A2 | MEDIUM-CHAIN LENGTH FATTY ACIDS, GLYCERIDES AND ANALOGUES AS NEUTROPHIL SURVIVAL AND ACTIVATION FACTORS | PROMETIC BIOSCIENCES INC. (CA) | 2002-10-24 | — | — | WO | claimed |
| US-5057148-A | Method of decalcifying rare earth metals formed by the reduction-diffusion process | GENERAL MOTORS CORPORATION (US) | 1991-10-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147599-A1 | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors | MYD88, CSF3R, MCTS1 | FABP3 561/4885CA1 2766/4885CES2 920/4885 |
| US-20060128800-A1 | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis | EPOR, CD14, HBG2 | FABP3 879/4885CA1 3011/4885CES2 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.